

PublisherInfo		
PublisherName	:	BioMed Central
PublisherLocation	:	London
PublisherImprintName	:	BioMed Central

## Articles selected in July 2004

ArticleInfo		
ArticleID	:	924
ArticleDOI	:	10.1186/bcr925
ArticleCitationID	:	E15
ArticleSequenceNumber	:	20
ArticleCategory	:	Article selection
ArticleFirstPage	:	1
ArticleLastPage	:	3
ArticleHistory	:	RegistrationDate : 2004-8-23 OnlineDate : 2004-8-23
ArticleCopyright	:	The Author(s)2004
ArticleContext	:	130586655

**Valerie Speirs**,<sup>Affl</sup>

Corresponding Affiliation: <sup>Affl</sup>

**Email:** v.speirs@leeds.ac.uk

---

<sup>Affl</sup> Molecular Medicine Unit, University of Leeds, St James's University Hospital, Leeds LS9 7TF, UK

---

## Articles selected from PubMed

## References

1. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. *Cancer Cell.* 2004, 5: 607-616. [[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\\_uids=15193263](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15193263)]
2. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. *J Natl Cancer Inst.* 2004, 96: 926-935. [[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\\_uids=15199112](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15199112)]
3. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J: HER-2 gene amplification can be acquired as breast cancer progresses. *Proc Natl Acad Sci U S A.* 2004, 101: 9393-9398. [[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\\_uids=15194824](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15194824)]
4. Elkin M, Orgel A, Kleinman HK: An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. *J Natl Cancer Inst.* 2004, 96: 875-878.

[[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\\_uids=15173272](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15173272)]

5. Arteaga CL, Baselga J: Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. *Cancer Cell.* 2004, 5: 525-531. [[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\\_uids=15193255](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15193255)]
6. Clayton H, Titley I, Vivanco Md M: Growth and differentiation of progenitor/stem cells derived from the human mammary gland. *Exp Cell Res.* 2004, 297: 444-460. [[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\\_uids=15212947](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15212947)]
7. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL: Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. *J Biol Chem.* 2004, 279: 24505-24513. [[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\\_uids=15044465](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15044465)]